SEELOS THERAPEUTICS, INC. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q3 2011 to Q3 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Seelos Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2011 to Q3 2022.
- Seelos Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2022 was -$19.6M, a 81.3% decline year-over-year.
- Seelos Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2014 was -$21.8M, a 28.6% decline from 2013.
- Seelos Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2013 was -$16.9M, a 45.6% increase from 2012.
- Seelos Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2012 was -$31.1M, a 71.8% decline from 2011.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)